Adult Leukemia Research Center

成人白血病研究中心

• 批准号: 7617986
• 负责人: FREDERICK APPELBAUM
• 金额: $ 527.34万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-22 至 2012-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7617986
• 关键词: Adult; Leukemia; Research; Center

DESCRIPTION (provided by applicant): Adult Leukemia Research Center Program Project The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT) as treatment for hematological malignancies. Specifically, we propose laboratory and clinical studies to increase the safety of transplantation, to enhance the anti-tumor effects of transplantation, to broaden the availability of transplantation, and to improve our ability to apply transplantation at the appropriate time in the course of disease. Six individual projects are proposed: 1. Nonmyeloablative Hematopoietic Cell Allotransplants 2. Immunogenetics of Graft-Versus-Host Disease 3. Prevention and Treatment of Graft-Versus-Host Disease 4. Resistance and Relapse of Chronic Myeloid Leukemia 5. Specific Adoptive Immunotherapy of Leukemia 6. Targeting Alloreactivity for Leukemia Eradication In addition, core support is requested in biostatistics, pathology, microbiology and virology, gastroenterology, pulmonary medicine and nephrology, cell processing, long-term follow-up, and administration. Our ability to successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of investigators all focused on the general topic of HCT; (2) strong preclinical research programs at our Center in support of this topic; and (3) the accrual of 450-500 transplant patients onto research protocols each year. Relevance to Public Health: This Program Project has direct relevance to the more than 18,000 patients who undergo allogeneic HCT for treatment of hematopoietic malignancies each year. The work proposed promises to make transplantation safer, more effective, increasingly available and more appropriately applied. Further, lessons learned from our planned studies will apply to issues of transplant tolerance, the molecular basis of malignant disease progression, and especially the immunotherapy of cancer.

描述（由申请人提供）：成人白血病研究中心计划项目 该计划项目的总体目标是改进同种异体造血细胞移植（HCT）作为血液恶性肿瘤的治疗方法。具体来说，我们建议进行实验室和临床研究，以提高移植的安全性，增强移植的抗肿瘤作用，扩大移植的可用性，并提高我们在病程的适当时间应用移植的能力。提议了六个单独的项目： 1. 非清髓性造血细胞同种异体移植 2. 移植物抗宿主病的免疫遗传学 3. 移植物抗宿主病的预防和治疗 4. 慢性粒细胞白血病的耐药和复发 5. 白血病的特异性过继免疫治疗 6. 针对白血病根除的同种异体反应性 此外，还需要生物统计学、病理学、微生物学和病毒学、胃肠病学、肺病学和肾病学、细胞处理、长期随访和管理等方面的核心支持。我们成功开展拟议工作的能力得益于：（1）存在一大批研究人员都专注于 HCT 的一般主题； (2) 我们中心支持该课题的强大临床前研究项目； (3) 每年有 450-500 名移植患者参与研究方案。与公共卫生的相关性：该计划项目与每年超过 18,000 名接受同种异体 HCT 治疗造血系统恶性肿瘤的患者直接相关。拟议的工作有望使移植更安全、更有效、越来越容易获得和更适当地应用。此外，从我们计划的研究中吸取的经验教训将适用于移植耐受问题、恶性疾病进展的分子基础，尤其是癌症的免疫治疗。